ORXOY Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (12 Apr 2024 @ 12:31):

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom...

Stats
Today's Volume	52.00
Average Volume	100.00
Market Cap	49.61M
EPS	$-0.967 ( 2023-09-30 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.24
ATR14	$0 (0.00%)

Orexo AB (publ) Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Orexo AB (publ) Financials

Annual	2023
Revenue:	$638.80M
Gross Profit:	$472.80M (74.01 %)
EPS:	$-3.73

Q4	2023
Revenue:	$166.00M
Gross Profit:	$124.90M (75.24 %)
EPS:	$-0.540

Q3	2023
Revenue:	$156.10M
Gross Profit:	$133.30M (85.39 %)
EPS:	$-0.970

Q2	2023
Revenue:	$157.70M
Gross Profit:	$140.50M (89.09 %)
EPS:	$-0.370

Financial Reports:

No articles found.

Orexo AB (publ)

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.